What To Expect From Intuitive Surgical’s Q1?

ISRG: Intuitive Surgical logo
Intuitive Surgical

Intuitive Surgical (NASDAQ: ISRG), a fast-growing robotic surgical platform company, is scheduled to report its Q1 2022 results on Thursday, April 21. We expect Intuitive Surgical to likely report revenue and earnings in-line with the consensus estimates. With the rise of the Omicron and Covid-19 cases in the U.S. in Q1, it is likely that Intuitive Surgical’s sales in certain geographies were adversely impacted. Like the previous waves, a higher number of cases can overwhelm the healthcare services in certain geographies, resulting in the postponement of elective surgeries, obstructing the revenue growth seen over the recent quarters. That said, our forecast indicates that ISRG stock is currently undervalued, as discussed below. Our interactive dashboard analysis on Intuitive Surgical Earnings Preview has additional details.

(1) Revenues expected to be in line with the consensus estimates

  • Trefis estimates Intuitive Surgical’s Q1 2022 revenues to be around $1.4 billion, aligning with the consensus estimate. 
  • The surge in Covid-19 cases due to the spread of Omicron in Q1 may adversely impact the overall revenue growth for the company.
  • That said, now that that wave has subsided, the company will likely see better revenue growth over the coming quarters.
  • Looking at Q4 2021, the company saw its sales grow 17% y-o-y to $1.6 billion. This growth was led by a 12% y-o-y increase in the installed base to 6,730 systems in Q4.
  • Our dashboard on Intuitive Surgical Revenues has more details.
Relevant Articles
  1. Here’s Why Intuitive Surgical Stock Is A Better Pick Over Its Peer
  2. Will Intuitive Surgical Stock Rise Post Q4?
  3. Pick Either Intuitive Surgical Or Its Industry Peer – Both May Offer Similar Returns
  4. What’s Next For Intuitive Surgical Stock After Upbeat Q3?
  5. What To Expect From Intuitive Surgical’s Q3?
  6. Should You Buy Intuitive Surgical Stock Over This Healthcare Company?

(2) EPS likely to align with the consensus estimates

  • Intuitive Surgical’s Q1 2022 adjusted earnings per share (EPS) is expected to be $1.08 per Trefis analysis, in line with the consensus estimate.
  • The company’s adjusted net income of $477 million in Q4 2021 reflected a 10% rise from its $434 million figure in the prior-year quarter, as the sales growth was partly offset by operating margin contraction.
  • The company’s operating margins contracted over 200 bps y-o-y to 29% in Q4.
  • Our dashboard on Intuitive Surgical’s Operating Income has more details.
  • For the full-year 2022, we expect the adjusted EPS to be higher at $5.00 compared to EPS of $4.90 in 2021.

(3) ISRG stock looks undervalued

  • We estimate Intuitive Surgical’s Valuation to be around $345 per share, which is 25% above the current market price of $276.
  • This represents a forward P/E multiple of 69x for the company based on our 2022 EPS forecast of $5.00.
  • Investors have assigned a high trading multiple for ISRG stock, given the strong revenue and earnings growth over the past years.
  • Note: P/E Multiples are based on Share Price at the end of the year and reported (or expected) Adjusted Earnings for the full year

While ISRG stock looks undervalued, it is helpful to see how Intuitive Surgical’s Peers fare on metrics that matter. You will find other valuable comparisons for companies across industries at Peer Comparisons.

Furthermore, the Covid-19 crisis has created many pricing discontinuities which can offer attractive trading opportunities. For example, you’ll be surprised how counter-intuitive the stock valuation is for Medtronic vs. Ferro.

What if you’re looking for a more balanced portfolio instead? Our high-quality portfolio and multi-strategy portfolio have beaten the market consistently since the end of 2016.

Returns Apr 2022
MTD [1]
YTD [1]
Total [2]
 ISRG Return -8% -23% 292%
 S&P 500 Return -3% -8% 96%
 Trefis Multi-Strategy Portfolio -3% -10% 253%

[1] Month-to-date and year-to-date as of 4/19/2022
[2] Cumulative total returns since the end of 2016

Invest with Trefis Market-Beating Portfolios
See all Trefis Price Estimates